University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Nola M. Hylton, PhD

Nola M. Hylton, PhD

Professor in Residence, Department of Radiology; and Leader, Breast Imaging Research Group, UCSF

Cancer Center Program Memberships

Breast Oncology

Research Summary

I am an imaging scientist and breast cancer researcher with broad experience in the area of biomedical research. Work in my laboratory focuses on the development of MRI techniques for breast cancer diagnosis and treatment response assessment. My laboratory works closely with a multi-disciplinary team of radiologists, surgeons, oncologists, basic science researchers and advocates to optimize MRI methods for the clinical management of breast cancer patients. The overall goal of our interdisciplinary research program is to develop imaging-based biomarkers that can be used in combination with clinical and molecular information to individualize treatment strategies.

I lead as Principal Investigator, the multi-center ACRIN trials 6657 and 6698, evaluating dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI respectively, for assessing treatment response as part of the ISPY-1 and ISPY-2 neoadjuvant breast cancer trials. Under an NCI Academic-Industrial Partnership (AIP) grant with commercial partner Hologic, Inc., (R01 CA132870), my laboratory developed and deployed a software platform for real-time measurement of breast tumor response using DCE-MRI, for use in clinical trials. The Hologic software received FDA IDE approval in 2010 and is now incorporated in the response-adaptive patient randomization engine of ISPY-2. Under prior funding from the NCI Quantitative Imaging Network (QIN) (U01 CA151235), my laboratory led efforts to improve the integration of quantitative imaging (QI) in breast cancer clinical trials through the development of standards and quality control processes and improved diffusion-weighted MRI approaches for tumor response measurement.

As an applied scientist involved in the early development of breast MRI, I believe I bring a unique perspective and appreciation of the factors that drive and shape the development of new breast imaging technologies. I have served on and chaired numerous grant review panels in both the areas of medical imaging and breast cancer research.

I am an active educator and faculty member at UCSF and in the UCSF/UC Berkeley Bioengineering Graduate Program and I teach formally in the UCSF Master’s in Biomedical Imaging degree program. I have been involved in the training and research supervision of graduate students, post-doctoral fellows and junior faculty for over 20 years.

Education

Massachusetts Institute of Technology (M.I.T.), B.S., 1979, Chemical Engineering
Stanford University, Ph.D., 1985, Applied Physics


Professional Experience

  • 1985 - 1992
    Assistant Professor in Residence, Department of Radiology, University of California, San Francisco
  • 1995 - 2002
    Associate Adjunct Professor, Department of Radiology, University of California, San Francisco 
  • 2002 - present
    Professor in Residence, Department of Radiology, University of California, San Francisco

 

Honors & Awards

  • 2010
    Komen Scholar, Komen for the Cure
  • 2013
    Distinguished Lectureship Award, Sigma Xi
  • 2013
    Distinguished Investigator Award, Academy of Radiology Research
  • 2017
    Fellow, International Society of Magnetic Resonance in Medicine

Selected Publications

  1. Jung S, Goloubeva O, Hylton N, Klifa C, LeBlanc E, Shepherd J, Snetselaar L, Van Horn L, Dorgan JF. Intake of dietary carbohydrates in early adulthood and adolescence and breast density among young women. Cancer Causes Control. 2018 May 25.
    View on PubMed
  2. Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol. 2018 Apr 30; 1-10.
    View on PubMed
  3. Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham). 2018 01; 5(1):011014.
    View on PubMed
  4. Ray KM, Kerlikowske K, Lobach IV, Hofmann MB, Greenwood HI, Arasu VA, Hylton NM, Joe BN. Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices. Radiology. 2018 03; 286(3):822-829.
    View on PubMed
  5. Newitt DC, Malyarenko D, Chenevert TL, Quarles CC, Bell L, Fedorov A, Fennessy F, Jacobs MA, Solaiyappan M, Hectors S, Taouli B, Muzi M, Kinahan PE, Schmainda KM, Prah MA, Taber EN, Kroenke C, Huang W, Arlinghaus LR, Yankeelov TE, Cao Y, Aryal M, Yen YF, Kalpathy-Cramer J, Shukla-Dave A, Fung M, Liang J, Boss M, Hylton N. Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network. J Med Imaging (Bellingham). 2018 Jan; 5(1):011003.
    View on PubMed
  6. Bane O, Hectors SJ, Wagner M, Arlinghaus LL, Aryal MP, Cao Y, Chenevert TL, Fennessy F, Huang W, Hylton NM, Kalpathy-Cramer J, Keenan KE, Malyarenko DI, Mulkern RV, Newitt DC, Russek SE, Stupic KF, Tudorica A, Wilmes LJ, Yankeelov TE, Yen YF, Boss MA, Taouli B. Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study. Magn Reson Med. 2018 May; 79(5):2564-2575.
    View on PubMed
  7. Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017; 3:31.
    View on PubMed
  8. O'Sullivan TD, Cerussi A, Durkin A, Hill B, Hylton N, Yodh AG, Carp SA, Boas D, Jiang S, Paulsen KD, Pogue B, Roblyer D, Yang W, Tromberg BJ. Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial J Biomed Opt. 2017 Dec 01; 22(12):121604.
    View on PubMed
  9. Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Breast Cancer. 2017 06; 17(3):e155-e159.
    View on PubMed
  10. Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging. 2017 Jul; 46(1):290-302.
    View on PubMed
  11. Farahani K, Kalpathy-Cramer J, Chenevert TL, Rubin DL, Sunderland JJ, Nordstrom RJ, Buatti J, Hylton N. Computational Challenges and Collaborative Projects in the NCI Quantitative Imaging Network. Tomography. 2016 Dec; 2(4):242-249.
    View on PubMed
  12. Wilmes LJ, Li W, Shin HJ, Newitt DC, Proctor E, Harnish R, Hylton NM. Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. Tomography. 2016 Dec; 2(4):438-447.
    View on PubMed
  13. Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography. 2016 Dec; 2(4):378-387.
    View on PubMed
  14. Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman PA, Yodh AG, Chung SH, Schnall M, Snyder BS, Hylton N, Boas DA, Carp SA, Isakoff SJ, Mankoff D. Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Res. 2016 10 15; 76(20):5933-5944.
    View on PubMed
  15. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22.
    View on PubMed
  16. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
    View on PubMed
  17. Bertrand KA, Baer HJ, Orav EJ, Klifa C, Kumar A, Hylton NM, LeBlanc ES, Snetselaar LG, Van Horn L, Dorgan JF. Early Life Body Fatness, Serum Anti-Müllerian Hormone, and Breast Density in Young Adult Women. Cancer Epidemiol Biomarkers Prev. 2016 07; 25(7):1151-7.
    View on PubMed
  18. Keenan KE, Peskin AP, Wilmes LJ, Aliu SO, Jones EF, Li W, Kornak J, Newitt DC, Hylton NM. Variability and bias assessment in breast ADC measurement across multiple systems. J Magn Reson Imaging. 2016 Oct; 44(4):846-55.
    View on PubMed
  19. Keenan KE, Wilmes LJ, Aliu SO, Newitt DC, Jones EF, Boss MA, Stupic KF, Russek SE, Hylton NM. Design of a breast phantom for quantitative MRI. J Magn Reson Imaging. 2016 Sep; 44(3):610-9.
    View on PubMed
  20. Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS One. 2016; 11(2):e0142047.
    View on PubMed

Go to UCSF Profiles, powered by CTSI